NextCure Future Growth
Future criteria checks 0/6
NextCure's earnings are forecast to decline at 2.1% per annum while its annual revenue is expected to grow at 51% per year. EPS is expected to grow by 27.8% per annum.
Key information
-2.1%
Earnings growth rate
27.8%
EPS growth rate
Biotechs earnings growth | 20.7% |
Revenue growth rate | 51.0% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 25 Mar 2024 |
Recent future growth updates
Recent updates
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Mar 23We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Dec 09Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?
Aug 23Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?
May 10We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Nov 22Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)
Aug 09NextCure GAAP EPS of -$0.59
Aug 04We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate
May 02NextCure: Large Upside With Downside Protected By Cash Pile
Sep 29NextCure (NXTC) Presents at 7th Annual Truist Securities Life Sciences Summit - Slideshow
May 10NextCure EPS misses by $0.01
May 06Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like
Feb 12NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares
Jan 08NextCure provides update on NC318 clinical program
Dec 17Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -58 | -73 | N/A | 2 |
12/31/2025 | N/A | -50 | -63 | N/A | 4 |
12/31/2024 | N/A | -47 | -48 | N/A | 4 |
12/31/2023 | N/A | -63 | -54 | -53 | N/A |
9/30/2023 | N/A | -66 | -53 | -51 | N/A |
6/30/2023 | N/A | -70 | -55 | -53 | N/A |
3/31/2023 | N/A | -70 | -55 | -53 | N/A |
12/31/2022 | N/A | -75 | -56 | -54 | N/A |
9/30/2022 | N/A | -74 | -61 | -58 | N/A |
6/30/2022 | N/A | -73 | -58 | -56 | N/A |
3/31/2022 | N/A | -73 | -61 | -59 | N/A |
12/31/2021 | N/A | -69 | -60 | -57 | N/A |
9/30/2021 | N/A | -68 | -53 | -50 | N/A |
6/30/2021 | N/A | -66 | -57 | -53 | N/A |
3/31/2021 | N/A | -63 | -55 | -48 | N/A |
12/31/2020 | 22 | -37 | -52 | -45 | N/A |
9/30/2020 | 24 | -32 | -56 | -49 | N/A |
6/30/2020 | 26 | -24 | -47 | -41 | N/A |
3/31/2020 | 27 | -18 | -43 | -39 | N/A |
12/31/2019 | 6 | -34 | -39 | -36 | N/A |
9/30/2019 | 4 | -30 | -8 | -3 | N/A |
6/30/2019 | 3 | -27 | -4 | 0 | N/A |
3/31/2019 | 1 | -24 | 2 | 6 | N/A |
12/31/2018 | N/A | -23 | 5 | 8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NXTC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NXTC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NXTC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NXTC is forecast to have no revenue next year.
High Growth Revenue: NXTC is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NXTC's Return on Equity is forecast to be high in 3 years time